0

0

0

0

0

0

0

0

0

videos | IST

Macquarie's 3 pharma bets and what it sees as the next trigger

Macquarie in its report said that it has initiated coverage on three pharmaceutical companies – Divi's Laboratories, Syngene and Solara.
India commands under 4 percent share of global CRAMS market. Macquarie believes that CRAMS is a multi-decade opportunity for Indian companies and Divi's Laboratories, Syngene are well placed for that.
Alankar Garude, Research Analyst at Macquarie Capital Securities gives more details on the report.